- Home
- STTK vs MVT Comparison
STTK vs MVT Comparison
Compare STTK & MVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | STTK | MVT |
|---|---|---|
| Founded | 2016 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Bankers/Brokers/Service |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 275.9M | 225.5M |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | STTK | MVT |
|---|---|---|
| Price | $4.01 | $10.97 |
| Analyst Decision | Buy | |
| Analyst Count | 7 | 0 |
| Target Price | ★ $6.20 | N/A |
| AVG Volume (30 Days) | ★ 893.1K | 49.7K |
| Earning Date | 11-06-2025 | 01-01-0001 |
| Dividend Yield | N/A | ★ 4.15% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,000,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.69 | $8.96 |
| 52 Week High | $4.89 | $11.17 |
Technical Indicators
Market Signals| Indicator | STTK | MVT |
|---|---|---|
| Relative Strength Index (RSI) | 49.25 | 62.00 |
| Support Level | $3.92 | $10.66 |
| Resistance Level | $4.46 | $10.86 |
| Average True Range (ATR) | 0.35 | 0.11 |
| MACD | -0.12 | 0.01 |
| Stochastic Oscillator | 20.64 | 84.85 |
Price Performance
Historical ComparisonAbout STTK Shattuck Labs Inc.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.
About MVT Blackrock MuniVest Fund II Inc.
Blackrock Munivest Fund II Inc is a closed-end management investment company. The fund's objective is to provide shareholders with as high a level of current income exempt from U.S. federal income taxes as is consistent with its investment policies and prudent investment management. The company invests in Transportation, Health, Utilities, Education, Housing, and other sectors.